Differential Expression of HER2 and SKP2 in Benign and Malignant Colorectal Lesions

Abstract

with younger cases usually complicate polyposis and ulcerative colitis (El-Bolkainy et al., 2013). The outcome of CRC patients has significantly improved over the past decades, reflecting continuous progress in understanding its biology, epidemiology, prevention, early diagnosis and treatment (Siegel et al., 2017), but the identification of clinically actionable oncogenic drivers and related predicted biomarkers are largely elusive (Zhang et al., 2020). CRC is a tumor that develops from the progression of acquired or hereditary premalignant lesions. It arises from interactions among different risk factors (environmental,

HER2 overexpression/amplification status in colorectal cancer: a comparison between immunohistochemistry and fluorescence in situ hybridization using five different immunohistochemical scoring criteria

“…Therefore, the IRS-p ranges from 0 to 9, while the IRS-m ranges from 0 to 24. Then, both IRS-p and IRS-m were classi ed into IHC 1+ (IRS-p score 1-2, IRS-m score 1-3), IHC 2+ (IRSp score 3-7, IRS-m score 4-8), and IHC 3+ (IRS-p score 8-9, IRS-m score [12][13][14][15][16][17][18][19][20][21][22][23][24]. IHC scores of 0 and 1+ were considered as being "HER2 negative", IHC score of 2+ was considered as being "HER2 equivocal", and IHC score of 3+ was considered as being "HER2-positive".…”

“…They de ned three conditions of HER2 positivity as follows (HERACLES criteria): (1) a HER2 immunohistochemical (IHC) 3 + score in ≥ 50% of CRC cells; (2) a HER2 IHC 3 + score in 10%-50% of the CRC cells, and a uorescence in situ hybridization (FISH) HER2/CEP17 ≥ 2.0 in ≥ 50% of CRC cells; (3) more than 50% of CRC cells with a HER2 IHC 2 + score and a FISH HER2/CEP17 ≥ 2.0. However, to date, HER2 diagnostic criteria for gastroesophageal adenocarcinoma (GEA criteria) 16 or other independent HER2 IHC scoring systems 21,22 have also been used in CRC HER2 studies. Moreover, the prognostic role of HER2 in CRC remains controversial.…”

HER2 overexpression/amplification status in colorectal cancer: a comparison between immunohistochemistry and fluorescence in situ hybridization using five different immunohistochemical scoring criteria

“…They defined three conditions of HER2 positivity as follows (HERACLES criteria): (1) a HER2 immunohistochemical (IHC) 3 + score in ≥ 50% of CRC cells; (2) a HER2 IHC 3 + score in 10–50% of the CRC cells, and a fluorescence in situ hybridization (FISH) HER2/CEP17 ≥ 2.0 in ≥ 50% of CRC cells; (3) more than 50% of CRC cells with a HER2 IHC 2 + score and a FISH HER2/CEP17 ≥ 2.0. However, to date, HER2 diagnostic criteria for gastroesophageal adenocarcinoma (GEA criteria) (Richman et al 2016 ) or other independent HER2 IHC scoring systems (Shabbir et al 2016 ; Moussa et al 2020 ) have also been used in CRC HER2 studies. Moreover, the prognostic role of HER2 in CRC remains controversial.…”